Es ist ein Fehler aufgetreten!
Novartis Aktie
| 91.81 CHF | -2.59CHF | -2.74% |
Aktionärsstruktur
| Inhaber | in % |
|---|---|
| Freefloat | 83.87 |
| Novartis AG | 10.38 |
| Sandoz Family Foundation | 3.53 |
| Novartis Foundation For Employee Participation | 2.14 |
| UBS Asset Management Switzerland AG | 2.09 |
| Government Pension Fund - Global (the) | 2.09 |
| Vanguard Total International Stock Index Fund | 1.37 |
| American Funds Europacific Growth Fund | 0.79 |
| Vanguard Health Care Fund | 0.79 |
| Capital Income Builder | 0.77 |
| Csif (ch) Umbrella - Switzerland Total Market Index Blue | 0.69 |
| American Funds Capital World Growth & Income Fund | 0.59 |
| Vanguard Developed Markets Index Fund | 0.53 |
*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.
Personal
| 2015 | 2016 | 2017 | 2018 | 2019 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 118'700 | 118'393 | 121'597 | 125'161 | 103'914 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0.40 | 0.40 | 0.40 | 0.41 | 0.45 |
Bilanz (in Mio. EUR) - Aktiva
| 2015 | 2016 | 2017 | 2018 | 2019 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 22'868 | 25'339 | 27'489 | 35'058 | 28'570 |
| Summe Anlagevermögen | 99'076 | 100'247 | 99'977 | 109'132 | 81'944 |
| Summe Aktiva | 132'037 | 132'519 | 129'833 | 143'578 | 114'665 |
Bilanz (in Mio. EUR) - Passiva
| 2015 | 2016 | 2017 | 2018 | 2019 | |
|---|---|---|---|---|---|
| Gesamtverschuldung/ -verbindlichkeiten | 21'953 | 24'191 | 27'700 | 31'634 | 28'225 |
| Summe Fremdkapital | 54'838 | 56'403 | 57'498 | 66'003 | 60'872 |
| Summe Eigenkapital | 77'199 | 76'115 | 72'334 | 77'575 | 53'793 |
| Summe Passiva | 132'037 | 132'519 | 129'833 | 143'578 | 114'665 |
Adresse
| Lichtstrasse 35, 4056 Basel | |
| Telefon | +41 (61) 324-11-11 |
| Fax | +41 (61) 324-80-01 |
| Internet | http://www.novartis.com |
Management
|
Ameet Mallik
Head-Global Marketing, Value & Access |
|
Andreas von Planta
Independent Non-Executive Director |
|
Ann Marie Fudge
Independent Non-Executive Director |
|
Bertrand Bodson
Chief Digital Officer |
|
Charles L. Sawyers
Independent Non-Executive Director |
|
Charlie Hough
VP & Global Head-Strategy |
|
Charlotte Pamer-Wieser
Secretary |
|
Dan Bar-Zohar
Global Head-Neuroscience Development |
|
David Lebwohl
SVP & Franchise Global Program Head |
|
Elizabeth Theophille
Chief Technology & Digital Officer |
|
Enrico Cipro Vanni
Vice Chairman |
|
Frans van Houten
Independent Non-Executive Director |
|
Hans Jörg Reinhardt
Independent Non-Executive Chairman |
|
Harry Werner Kirsch
Chief Financial Officer |
|
James E. Bradner
President-NIBR |
|
Janneke van der Kamp
Member Executive Committee |
|
Jeffrey Engelman
Vice President & Global Head-Oncology NIBR |
|
John Tsai
Chief Medical Officer |
|
Klaus Moosmayer
Chief Ethics Risk & Compliance Officer |
|
Lilli Petruzzelli
Global Head-Immuno-Oncology |
|
Mark Levick
Global Head |
|
Mark Never
Head-Cluster Western Europe |
|
Mary Elizabeth Doherty
Independent Non-Executive Director |
|
Mimi Huizinga
VP & Head-Strategic Data |
|
Nancy C. Andrews
Independent Non-Executive Director |
|
Natacha Theytaz
Head-Internal Audit |
|
Patrice Bula
Director |
|
Samir Shah
Global Head-Investor Relations |
|
Samit Hirawat
Head- Global Oncology Development |
|
Shannon Thyme Klinger
Group General Counsel |
|
Srikant T. Madhav Datar
Independent Non-Executive Director |
|
Steffen Lang
Global Head-Technical Operations |
|
Stephen Moran
Global Head-Strategy |
|
Steven Baert
Chief People & Organization Officer |
|
Ton Büchner
Independent Non-Executive Director |
|
Vasant Narasimhan
Chief Executive Officer |
|
William Thomas Winters
Independent Non-Executive Director |
